Pharma

Your Article Summary

See Latest Articles

APP Pharmaceuticals Receives Approval for Idarubicin HCI Injection
American Pharmaceutical Partners, 08/11/09

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. , announced that it has received approval from the U.S. Food and Drug Administration to market idarubicin hydrochloride injection in three dosage strengths. Idarubicin is therapeutically equivalent to the reference drug Idamycin PFS injection, which is marketed by the innovator Pfizer, Inc.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/08/09

Recombinant Human Erythropoietin, Epogin Injection Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09

Synthon announces European approvals for Raloxifene
Synthon, 12/08/09

 See all of Drug/Product Approvals